Myasthenia Gravis: Cyclic and Continuous Dosing of Intravenous Efgartigimod
Elena Cortes, from Hospital de la Santa Creu i Sant Pau in Barcelona, presents in this MEDtalk the results of the ADAPT NXT study. This study analyzes the efficacy, safety, and tolerability of 10 mg/kg intravenous efgartigimod administered in a cyclic or continuous dosing regimen.
